<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03248479</url>
  </required_header>
  <id_info>
    <org_study_id>5F9005</org_study_id>
    <nct_id>NCT03248479</nct_id>
  </id_info>
  <brief_title>Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies</brief_title>
  <official_title>A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Forty Seven, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Forty Seven, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate magrolimab, a monoclonal antibody which is designed to block a
      protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with
      magrolimab may enable the body's immune system to find and destroy the cancer cells. In this
      study, magrolimab may be given alone or in combination with azacitidine to patients with
      acute myeloid leukemia (AML) or higher risk myelodysplastic syndrome (MDS). Azacitidine is a
      drug used for treatment of AML or MDS in patients who are not eligible for typical
      chemotherapy.

      The major aims of the study are: to confirm the safety and tolerability of magrolimab
      monotherapy in a relapsed/refractory AML and MDS population, and of magrolimab in combination
      with azacitidine in previously untreated AML and MDS; to evaluate the efficacy of magrolimab
      monotherapy in relapsed/refractory AML/MDS, and of magrolimab in combination with azacitidine
      in previously untreated AML/MDS, as measured by the objective response rate; and to evaluate
      the safety, tolerability, and efficacy of magrolimab monotherapy or combination with
      azacitidine in low-risk MDS patients as measured by RBC transfusion independence rate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 12, 2017</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Adverse events according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 or customized AE severity grading as defined in the protocol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>Objective Response Rate as defined by the Investigator according to protocol-specified criteria based on European LeukemiaNet (ELN) AML recommendations (Döhner 2017), International Working Group (IWG) AML response criteria (Cheson 2003), or IWG MDS response criteria (Cheson 2006) where appropriate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>8 week RBC transfusion independence rate</measure>
    <time_frame>8 weeks</time_frame>
    <description>• 8 week RBC transfusion independence rate for patients with low risk MDS as defined by the lack of RBC transfusions for at least an 8 week consecutive period at any time after starting therapy</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">257</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Relapsed/Refractory AML or MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with relapsed or refractory AML or intermediate/high risk MDS will receive magrolimab monotherapy or magrolimab in combination with azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment-naive Unfit AML or MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with previously untreated AML who are ineligible for standard induction chemotherapy, or previously untreated intermediate/high risk MDS, will receive magrolimab in combination with azacitidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rollover</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients on a previous AML Phase 1 trial (SCI-CD47-002) with clinical benefit on magrolimab treatment will receive magrolimab monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RBC transfusion-dependent low-risk MDS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Red Blood Cell (RBC) transfusion-dependent low-risk MDS patients will receive magrolimab monotherapy or magrolimab in combination with azacitidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magrolimab</intervention_name>
    <description>Magrolimab will be administered up to twice weekly.</description>
    <arm_group_label>RBC transfusion-dependent low-risk MDS</arm_group_label>
    <arm_group_label>Relapsed/Refractory AML or MDS</arm_group_label>
    <arm_group_label>Rollover</arm_group_label>
    <arm_group_label>Treatment-naive Unfit AML or MDS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine will be administered daily for 7 days in each 28-day cycle.</description>
    <arm_group_label>Relapsed/Refractory AML or MDS</arm_group_label>
    <arm_group_label>Treatment-naive Unfit AML or MDS</arm_group_label>
    <other_name>VIDAZA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>Azacitidine will be administered daily for 5 days in each 28-day cycle.</description>
    <arm_group_label>RBC transfusion-dependent low-risk MDS</arm_group_label>
    <other_name>VIDAZA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets the criteria below for the appropriate cohort:

               1. Relapsed/Refractory Cohorts: Pathologically confirmed relapsed or refractory
                  (primary refractory and/or relapsed refractory) AML or confirmed intermediate,
                  high, or very high risk MDS that is relapsed, refractory or intolerant to
                  conventional therapy

               2. Treatment-naïve/ Unfit Cohorts: Previously untreated patients with histological
                  confirmation of AML who are ineligible for treatment with a standard cytarabine
                  and anthracycline induction regimen; or previously untreated patients with
                  intermediate, high, or very high risk MDS. Prior and concurrent therapy with
                  hydroxyurea, oral etoposide, erythroid and/or myeloid growth factors is allowed.

               3. Rollover Cohort: Patients on active magrolimab therapy on the Phase 1 AML
                  (SCI-CD47-002) trial who are deriving clinical benefit by Investigator assessment

               4. RBC transfusion dependent low risk MDS cohort: Transfusion-dependent MDS patients
                  who are very low or low risk by IPSS-R with previous treatment with an erythroid
                  stimulating agent or lenalidomide.

          -  White blood cell (WBC) count ≤ 20 x 10E3/µL

          -  Adequate performance status and hematological, liver, and kidney function

        Exclusion Criteria:

          -  Prior treatment with CD47 or signal regulatory protein alpha (SIRPα) targeting agents
             (with exception of magrolimab for patients in the Rollover cohort).

          -  Treatment-naïve/Unfit Cohorts Only: Any prior anti-leukemic therapy (excluding
             hydroxyurea or oral etoposide), prior treatment with hypomethylating agents and/or low
             dose cytarabine.

          -  Acute promyelocytic leukemia.

          -  Known inherited or acquired bleeding disorders.

          -  Previous allogeneic hematopoietic stem cell transplant within 6 months prior to
             enrollment, active graft versus host disease (GVHD), or requiring transplant-related
             immunosuppression.

          -  Clinical suspicion of active central nervous system (CNS) involvement by leukemia

          -  Known active or chronic hepatitis B or C infection or HIV

          -  Pregnancy or active breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Chao, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Forty Seven, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark Chao, MD PhD</last_name>
    <phone>1-650-352-4150</phone>
    <email>medical@fortyseveninc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Xu, PhD</last_name>
    <phone>1-650-352-4150</phone>
    <email>medical@fortyseveninc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Monzr Al Malki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Tiffany Tanaka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Clinical and Translational Research Center (CTRC)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wanxing Chai-Ho</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chao Family Comprehensive Cancer Center - UC Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868-3298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Deepa Jeyakumar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Comprehensive Cancer Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brian Jonas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriel Mannis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Pollyea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Of Miami - Miller School Of Medicine, Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Terrence Bradley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center and Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Sallman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Richard Larson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amir Fathi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute/ Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel DeAngelo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Medical Center (HCA Midwest Health)</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Suman Kambhampati</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eunice Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College - New York-Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ellen K Ritchie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Lewis Silverman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joshua Zeidner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Harry Erba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic - Taussig Cancer Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karilyn Larkin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Adam Asch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology Centennial Clinic (Sarah Cannon Research Institute)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Donnellan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Baylor Charles A. Simmons Cancer Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew R Whiteley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Naval Daver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of WI Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guru Subramanian Guru Murthy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital, Oxford University</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paresh Vyas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 14, 2017</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>magrolimab</keyword>
  <keyword>CD47</keyword>
  <keyword>azacitidine</keyword>
  <keyword>Hu5F9-G4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

